Edoxaban‐induced enterocolitis: The first case report demonstrating distinct endoscopic and histological features [PDF]
DEN OpenDirect oral anticoagulants (DOACs), including edoxaban, are widely used for stroke prevention in atrial fibrillation and venous thromboembolism. While gastrointestinal bleeding and diarrhea are recognized adverse effects, DOAC‐induced enterocolitis has ...
Katsuya Endo +8 more
doaj +3 more sources
Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China study [PDF]
Frontiers in PharmacologyIntroductionNon–vitamin K antagonist oral anticoagulants (NOACs) are the first-line therapy to prevent ischaemic stroke in patients with atrial fibrillation (AF).
Xueyuan Guo +24 more
doaj +2 more sources
Edoxaban for stroke prevention in patients with atrial fibrillation: Of randomized and real-world evidence [PDF]
Indian Pacing and Electrophysiology JournalAtrial fibrillation (AF) is the most common chronic arrhythmia worldwide. AF related complications include ischemic stroke, which can be prevented for largely by the use of direct oral anticoagulants. This review focuses on the randomized trial and large
Joris R. de Groot
doaj +2 more sources
Postoperative D-dimer as a signal of venous thromboembolism in patients receiving Edoxaban after hip or knee arthroplasty [PDF]
Journal of Pharmaceutical Health Care and SciencesBackground Edoxaban is the only direct-acting oral anticoagulant (DOAC) indicated for preventing venous thromboembolism (VTE) in patients undergoing arthroplasty and can be administered for a short period (1–2 weeks).
Norito Nishiyama +5 more
doaj +2 more sources
Reactions Weekly, 2018 Ein weiteres «direktes» orales Antikoagulans, das weniger Blutungen verursacht als Warfarin. In welchem Ausmass sich die Studienresultate auf einen Vergleich mit dem in der Schweiz gebräuchlichen Phenprocoumon extrapolieren lassen, ist nicht klar.
Lenka Špinarová +2 more
+6 more sources
Hospital Pharmacy, 2015 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +3 more sources
Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
Frontiers in Pharmacology, 2021 Background and Purpose: Edoxaban exposure varies across different ethnicities. The purpose of our study was to examine the risk factors associated with high or low edoxaban concentrations in Asian populations.Methods: Participants with atrial ...
Shin-Yi Lin +8 more
doaj +1 more source
Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. [PDF]
PLoS ONE, 2018 Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant human FXa, rapidly reverses the anticoagulation effects of direct and indirect FXa inhibitors.To evaluate
Genmin Lu +9 more
doaj +1 more source
Edoxaban dosing patterns in real life practice – Results from the DRESDEN NOAC REGISTRY
Thrombosis Update, 2021 Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism treatment or stroke prevention in atrial fibrillation.
Jan Beyer-Westendorf +5 more
doaj +1 more source
Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats
TH Open, 2021 Coagulation–fibrinolytic system activity shows daily rhythmicity, with hypercoagulability in the morning and hypocoagulability in the evening. Consequently, the efficacy of anticoagulants may be influenced by their dosing time.
Naoto Nagata +3 more
doaj +1 more source